SEC For	m 4															
FORM 4 UNITED				TATES SECURITIES AND EXCHANGE COMMISSION											1	
				Washington, D.C. 20549									OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					T OF CHANGES IN BENEFICIAL OWNERSHIP								Estimat	OMB Number:         3235-0287           Estimated average burden            hours per response:         0.5		
				0	or Section 30(h) of the Investment Company Act of 1940											
1. Name and Address of Reporting Person <sup>*</sup> <u>Ring Christine</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Nurix Therapeutics, Inc.</u> [NRIX ]							eck all applie Directo	cable)	10% Owne		
I	C/O NURIX THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 02/11/2021							X below)	General Counsel			
1700 OW	ENS STRI	EET, SUITE 205														
(Street) SAN CA 94158 FRANCISCO				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							<ul> <li>Individual or Joint/Group Filing (Check Applicable ine)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>				
(City) (State) (Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) Date (Month/D				9	Execution Date			, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 ar		Beneficia Owned F	ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) o (D)	r Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code ) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$38.97	02/11/2021		A		40,000		(1)	02/10/2031	Common Stock	40,000	\$0.00	40,000	D		

Explanation of Responses:

1. The stock option vests as to 1/48 of the total shares monthly beginning March 11, 2021 until the option is fully vested on February 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

## /s/ Christine Ring

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

02/12/2021 Date